PMID- 34755560
OWN - NLM
STAT- MEDLINE
DCOM- 20211111
LR  - 20220531
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 49
IP  - 11
DP  - 2021 Nov
TI  - Dihydroartemisinin inhibits IL-6-induced epithelial-mesenchymal transition in 
      laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/beta-catenin signaling 
      pathway.
PG  - 3000605211009494
LID - 10.1177/03000605211009494 [doi]
LID - 03000605211009494
AB  - OBJECTIVE: To explore whether dihydroartemisinin (DHA) can block interleukin 
      (IL)-6-induced epithelial-mesenchymal transition (EMT) in laryngeal squamous cell 
      carcinoma (LSCC). METHODS: The expression of SLUG, signal transducer and 
      activator of transcription 3 (STAT3), and microRNA (miR)-130b-3p was measured. In 
      addition, a dual-luciferase reporter assay was performed to examine the 
      interaction of miR-130b-3p with STAT3. RESULTS: We found that IL-6 can promote 
      EMT and invasion in LSCC cells, whereas DHA can inhibit these two processes. 
      However, DHA alone does not influence EMT and cancer invasion. Furthermore, DHA 
      upregulated miR-130b-3p, which can downregulate STAT3 and beta-catenin protein 
      expression and decrease the activity of the IL-6/STAT3 signaling pathway. 
      Moreover, we found that miR-130b-3p can target STAT3 directly. CONCLUSIONS: DHA 
      can block IL-6-triggered EMT and invasion in LSCC, and during these processes, 
      DHA increases miR-130b-3p expression to decrease the activation of the IL-6/STAT3 
      and beta-catenin signaling pathways. These findings may provide new insights into 
      strategies for suppressing and even preventing LSCC metastasis.
FAU - Sun, Yajing
AU  - Sun Y
AD  - Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
FAU - Lu, Xiuying
AU  - Lu X
AD  - Department of Otolaryngology Head and Neck Surgery, Bethune International Peace 
      Hospital, Shijiazhuang, Hebei, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Pathology, Bethune International Peace Hospital, Shijiazhuang, 
      Hebei, China.
FAU - Li, Xiaoming
AU  - Li X
AUID- ORCID: 0000-0002-0931-727X
AD  - Department of Otolaryngology Head and Neck Surgery, Bethune International Peace 
      Hospital, Shijiazhuang, Hebei, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Artemisinins)
RN  - 0 (Interleukin-6)
RN  - 0 (MicroRNAs)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - 0 (beta Catenin)
RN  - 6A9O50735X (artenimol)
SB  - IM
MH  - Artemisinins
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Epithelial-Mesenchymal Transition
MH  - Gene Expression Regulation, Neoplastic
MH  - *Head and Neck Neoplasms
MH  - Humans
MH  - Interleukin-6/genetics
MH  - *MicroRNAs/genetics
MH  - STAT3 Transcription Factor/genetics
MH  - Signal Transduction
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - beta Catenin/genetics
PMC - PMC8586195
OTO - NOTNLM
OT  - Dihydroartemisinin
OT  - epithelial-mesenchymal transition
OT  - interleukin-6
OT  - laryngeal squamous cell carcinoma
OT  - microRNA-130b-3p
OT  - signal transducer and activator of transcription 3
OT  - beta-catenin
COIS- Declaration of conflicting interest: The authors declare that there is no 
      conflict of interest.
EDAT- 2021/11/11 06:00
MHDA- 2021/11/12 06:00
PMCR- 2021/11/10
CRDT- 2021/11/10 08:44
PHST- 2021/11/10 08:44 [entrez]
PHST- 2021/11/11 06:00 [pubmed]
PHST- 2021/11/12 06:00 [medline]
PHST- 2021/11/10 00:00 [pmc-release]
AID - 10.1177_03000605211009494 [pii]
AID - 10.1177/03000605211009494 [doi]
PST - ppublish
SO  - J Int Med Res. 2021 Nov;49(11):3000605211009494. doi: 10.1177/03000605211009494.